XL Laboratories Private Limited Pharmaceutical Export Profile — India (DGFT 2022–2026)

Name: XL Laboratories Private Limited Pharmaceutical Export Portfolio Dataset — 4 Products, $1.6M FOB USD, India (DGFT 2022–2026)
Creator: TransData Nexus

Suresh Sormare

Explore

XL Laboratories Private Limited — Pharmaceutical Exporter Profile (2026) | 4 Products, $1.6M Trade | TransData Nexus

XL Laboratories Private Limited

Indian Pharmaceutical Exporter · Ayurvedic & Herbal Products Specialist · $1.6M Total Trade · DGFT Verified

XL Laboratories Private Limited is an Indian pharmaceutical exporter with a total trade value of $1.6M across 4 products in 4 therapeutic categories. Based on 69 verified export shipments from Indian Customs (DGFT) records, the company actively competes across multiple product segments. Top exports include Natural ($700.0K), Colchicine ($459.0K), Dextromethorphan ($390.6K).

XL Laboratories Private Limited — Export Portfolio & Destination Treemap

XL Laboratories Private Limited pharmaceutical export portfolio — 4 products across 4 therapeutic categories. Source: Indian Customs (DGFT).

Who is XL Laboratories Private Limited? — Company Overview & Market Position

XL Laboratories Private Limited, incorporated on March 16, 2000, is a privately held pharmaceutical company based in New Delhi, India. The company is registered under the Corporate Identification Number (CIN) U24239DL2000PTC104513. Its authorized and paid-up capital stands at ₹3.00 crore, reflecting a solid financial foundation. The registered office is located at DSM 430-431, DLF Tower, Shivaji Marg, New Delhi, Delhi 110015, India.

As of October 26, 2025, XL Laboratories Private Limited is led by two directors: Ashok Kumar Bhargava and Rahul Bhargava, who have been serving since February 11, 2002, and March 16, 2002, respectively. The company employs over 450 professionals, indicating a robust workforce dedicated to its operations. For more information, the company's official website is xlrem.com.

What Does XL Laboratories Private Limited Export? — Product Portfolio Analysis

Top Products by Export Value

1Natural$700.0K 2Colchicine

Product Portfolio — Top 4 by Export Value

XL Laboratories Private Limited exports 4 pharmaceutical products across 4 therapeutic categories.

#	Product	Category	Export Value	Shipments	Market Share	Rank
1	Natural	Ayurvedic & Herbal Products	$700.0K	14	2.7%	5
2	Colchicine	Lipid & Metabolism	$459.0K	39	2.2%	10
3	Dextromethorphan	Respiratory & OTC	$390.6K	13	2.6%	10
4	Melatonin	Nutritional Supplements	$67.8K	3	0.7%	14

XL Laboratories Private Limited exports 4 pharmaceutical products across 4 therapeutic categories with a total export value of $1.6M. The top category is Ayurvedic & Herbal Products (43.3% of portfolio), followed by Lipid & Metabolism (28.4%), indicating a concentrated portfolio with the top 5 products accounting for 100.0% of total export value.

XL Laboratories Private Limited — Corporate Profile & Information

Headquarters, ownership, manufacturing facilities, and key leadership

1Corporate Overview

2Manufacturing Facilities

XL Laboratories Private Limited operates manufacturing facilities in Bhiwadi, Rajasthan, and New Delhi, Delhi. These plants specialize in the production of pharmaceutical formulations, including tablets, hard gelatin capsules, soft gelatin capsules, oral liquids, and sachets. The company holds approvals from various regulatory bodies, such as EU GMP, PIC/s, TGA, and WHO GMP, ensuring compliance with international quality standards.

3Key Leadership

The leadership team at XL Laboratories Private Limited comprises:

Ashok Kumar Bhargava: Managing Director, appointed on February 11, 2002.

Rahul Bhargava: Director, appointed on March 16, 2002.

Under their guidance, the company has expanded its product portfolio and global presence, emphasizing quality and innovation in pharmaceutical manufacturing.

TransData Nexus Research · Government registries, company filings, regulatory databasesMar 2026

Where Does XL Laboratories Private Limited Export? — Destination Intelligence

Regulated market presence, emerging market penetration, and geographic strategy

1Regulated Markets

XL Laboratories Private Limited has established a significant presence in regulated markets, including the European Union (EU), United Kingdom (UK), Australia, and Brazil. The company has secured approvals such as EU GMP, TGA (Australia), ANVISA (Brazil), PIC/s, and Thai FDA, facilitating its entry into these markets. These certifications enable XL Laboratories to engage in contract manufacturing and license its intellectual property, with over 25 marketing authorizations in the regulated market space.

2Emerging Markets

In addition to its presence in regulated markets, XL Laboratories Private Limited has expanded its footprint into emerging markets across Africa, Latin America, Southeast Asia, China, Hong Kong, and the Indian subcontinent. The company's in-house Regulatory Department has been instrumental in obtaining more than 600 product registrations globally, including in these regions. This expansion is supported by the company's status as a Star Export House, granted by the Ministry of Commerce, Government of India, for outstanding performance in international markets.

3Geographic Strategy

XL Laboratories Private Limited — Manufacturing & Regulatory Profile

FDA status, WHO-GMP certification, EU GMP compliance, and regulatory track record

1FDA Status

As of the latest available data, XL Laboratories Private Limited has not reported any FDA facility registrations, approved Abbreviated New Drug Applications (ANDAs), or Drug Master File (DMF) filings. The company has not been subject to any FDA inspections, Form 483 observations, warning letters, or import alerts. This indicates that XL Laboratories has not yet entered the U.S. market or engaged in activities requiring FDA oversight.

2WHO & EU GMP

XL Laboratories Private Limited holds certifications from the World Health Organization (WHO) Good Manufacturing Practices (GMP) and the European Union (EU) GMP. These certifications affirm the company's adherence to international quality standards in pharmaceutical manufacturing. The company's manufacturing facilities have also secured approvals from the Pharmaceutical Inspection Co-operation Scheme (PIC/s), Therapeutic Goods Administration (TGA) in Australia, and Thai FDA, further demonstrating its commitment to quality and regulatory compliance.

3CDSCO & Indian Regulatory

XL Laboratories Private Limited — Competitive Positioning Among Indian Pharma Exporters

Market share comparison, key differentiators, and strategic analysis

1Competitive Landscape

In the pharmaceutical manufacturing sector, XL Laboratories Private Limited faces competition from both domestic and international companies. Key competitors include established Indian pharmaceutical manufacturers and global entities with a presence in the same therapeutic categories. While specific market share data is not available, XL Laboratories' focus on quality, regulatory compliance, and a diversified product portfolio positions it competitively in the market. The company's ability to secure approvals in regulated markets and its extensive global reach are significant competitive advantages.

2Key Differentiators

XL Laboratories Private Limited distinguishes itself through its commitment to quality, as evidenced by its certifications from WHO GMP, EU GMP, PIC/s, TGA, and Thai FDA. The company's in-house Regulatory Department has been instrumental in obtaining over 600 product registrations globally, facilitating its presence in more than 32 countries. Additionally, XL Laboratories' status as a Star Export House, granted by the Ministry of Commerce, Government of India, underscores its outstanding performance in international markets.

3Strategic Position

Buyer Due Diligence Brief — Evaluating XL Laboratories Private Limited as a Supplier

Track record assessment, certifications to verify, and pre-order checks

1Supplier Assessment

XL Laboratories Private Limited has demonstrated a consistent track record in pharmaceutical manufacturing, with a total export value of $1.6 million USD across 69 shipments. The company's product portfolio spans four therapeutic categories, with a concentration in Ayurvedic & Herbal Products (43.3%), Lipid & Metabolism (28.4%), and Respiratory & OTC (24.2%). The top five products include Natural ($700K, Rank #5, 2.7% market share), Colchicine ($459K, Rank #10, 2.2% market share), Dextromethorphan ($391K, Rank #10, 2.6% market share), and Melatonin ($68K, Rank #14, 0.7% market share). This diverse product range and consistent export performance indicate reliability and capacity in meeting international demand.

2Certifications to Verify

Importers should verify the following certifications to ensure product quality and regulatory compliance:

WHO GMP: Confirms adherence to World Health Organization Good Manufacturing Practices.

EU GMP: Indicates compliance with European Union Good Manufacturing Practices.

Frequently Asked Questions — XL Laboratories Private Limited

How many pharmaceutical products does XL Laboratories Private Limited export from India?

XL Laboratories Private Limited exports 4 pharmaceutical products across 4 therapeutic categories. The top exports are Natural ($700.0K), Colchicine ($459.0K), Dextromethorphan ($390.6K), Melatonin ($67.8K). Total export value is $1.6M.

What is XL Laboratories Private Limited's total pharmaceutical export value?

XL Laboratories Private Limited's total pharmaceutical export value is $1.6M, based on 69 verified shipments recorded in Indian Customs (DGFT) data.

What therapeutic categories does XL Laboratories Private Limited cover?

XL Laboratories Private Limited exports across 4 therapeutic categories. The largest are Ayurvedic & Herbal Products (43.3%, 1 products), Lipid & Metabolism (28.4%, 1 products), Respiratory & OTC (24.2%, 1 products).

Get Full XL Laboratories Private Limited Export Intelligence

Access shipment-level details, pricing data, buyer connections, product breakdown, and competitive analysis. TransData Nexus provides verified Indian Customs (DGFT) data trusted by pharmaceutical trade professionals worldwide.

Contact for Data Access Request Live Demo

Official References & Regulatory Resources

Verify manufacturer licensing, GMP certification, and export registration with the agencies above.

Research Methodology & Data Transparency

Suresh Sormare

Verified Author

Pharmaceutical Export-Import Analyst & Trade Intelligence Expert

Suresh Sormare is a pharmaceutical export-import analyst with deep expertise in Indian Customs (DGFT) data, HS code classification, and global pharmaceutical supply chains. His analysis covers 10M+ shipment records across 150+ countries and is used by manufacturers, procurement agencies, and trade consultants worldwide. Suresh specializes in identifying verified suppliers and buyers from customs records, mapping bilateral pharmaceutical trade corridors, analyzing tariff structures and regulatory frameworks across 170+ destination markets, and benchmarking competitive positioning for finished pharmaceutical formulations. His methodology combines granular customs transaction data with regulatory intelligence from FDA, EMA, WHO, CDSCO, and 40+ national drug authorities to deliver actionable trade insights for the pharmaceutical formulations sector.

linkedin.com/in/sureshsormare

Primary Data Source

All trade data is sourced from Indian Customs (DGFT) official shipping bill records — the authoritative government database for India's pharmaceutical trade. Each verified record contains exporter name, consignee (buyer) name, detailed product description, quantity, declared FOB value (USD), port of loading, destination country, and shipment date.

Data Source & Methodology

Trade data sourced from Indian Customs (DGFT) export shipment records. Values represent FOB export value in USD. Market share calculated relative to total Indian pharmaceutical exports per product category. For current shipment-level data, contact TransData Nexus.